Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma

Anticancer Research

Volumn 28, Issue 6 A, 2008, Pages 3637-3645

  Ogawa, Fumi ^a   Takaoka, Hiroo ^a   Iwai, Soichi ^a   Aota, Keiko ^a   Yura, Yoshiaki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Herpes simplex virus; Oncolytic virotherapy; Oral squamous cell carcinoma; Syncytial formation

Indexed keywords

LACTATE DEHYDROGENASE; ONCOLYTIC HERPES VIRUS; ONCOLYTIC HERPES VIRUS HF; ONCOLYTIC HERPES VIRUS R849; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CARCINOMA CELL; CELL FUSION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ASSAY; ENZYME RELEASE; FEMALE; GAMMA 1 34.5 GENE; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MOUSE; MOUTH CARCINOMA; NONHUMAN; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; SECONDARY INFECTION; SQUAMOUS CELL CARCINOMA; STRAIN DIFFERENCE; SUBCUTANEOUS TISSUE TUMOR; VIRUS GENE; VIRUS INFECTION; VIRUS MUTANT; VIRUS STRAIN;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; ONCOLYTIC VIROTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149173504     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Vokes EE, Weichselbaum RR, Lippman SM and Hong WK: Head and neck cancer. N Engl J Med 328: 184-194, 1993.
2. Smith BD and Haffty BG: Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Radiat Oncol Investig 7: 125-144, 1999.
3. Mineta T, Rabkin SD, Yazaki T, Hunter WD and Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant glioma. Nat Med 1: 938-943, 1995.
4. Carew JF, Kooby DA, Halterman MW, Federoff HJ and Fong Y: Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 10: 1599-1606, 1999.
5. Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA and Fong Y: Effective treatment of head and neck squamous cell carcinoma by oncolytic herpes simplex virus. J Am Coll Surg 193: 12-21, 2001.
6. Kirn D, Marutuza RL and Zwiebel J: Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7: 781-787, 2001.
7. 134.5, gene nonessential for growth in culture. Science 250: 1262-1266, 1990.
8. He B, Gross M and Roizman B: The gamma(1) 34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 94: 843-848, 1997.
9. Farassati F, Yang AD and Lee PW: Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 3: 745-50, 2001.
10. Smith KD, Mezhir JJ, Bickenbach K, Veerapong J, Charron J, Posner MC, Roizman B and Weichselbaum RR: Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol 80: 1110-1120, 2006.
11. Veerapong J, Bickenbach KA, Shao MY, Smith KD, Posner MC, Roizman B and Weichselbaum RR: Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res 67: 8301-8306, 2007.
12. Ino Y, Saeki Y, Fukuhara H and Todo T: Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12: 643-652, 2006.
13. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D and Coombes RC: A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12: 6737-6747, 2006.
14. Chahlavi A, Todo T, Martuza RL and Rabkin SD: Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1: 162-169, 1999.
15. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR and Molnar-Kimber KL: Combained therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 10: 3013-3029, 1999.
16. Stanziale SF, Petrowsky H, Joe JK, Roberts GD, Zager JS, Gusani NJ, Ben-Porat L, Gonen M and Fong Y: Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by up-regulating ribonucleotide reductase. Surgery 132: 353-359, 2002.
17. Bennett JJ, Adusumilli P, Petrowsky H, Burt BM, Roberts G, Delman KA, Zager JS, Chou TC and Fong Y: Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J 18: 1001-1003, 2004.
18. Arlen PM, Pazdur M, Skarupa L, Rauckhorst M and Gulley JL: A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin Breast Cancer 7: 176-179, 2006.
19. Adusumilli PS, Chan MK, Hezel M, Yu Z, Stiles BM, Chou TC, Rusch VW and Fong Y: Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol 14: 258-269, 2007.
20. Takakuwa H, Goshima F, Nozawa N, Yoshikawa T, Kimata H, Nakao A, Nawa A, Kurata T, Sata T and Nishiyama Y: Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol 148: 813-825, 2003.
21. Nakao A, Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T, Goshima F and Nishiyama Y: Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann Oncol 15: 988-989, 2004.
22. Fujimoto Y, Mizuno T, Sugiura S, Goshima F, Kohno S, Nakashima T and Nishiyama Y: Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinomas. Acta Otolaryngol 126: 1115-1117, 2006.
23. Nishiyama Y, Kimura H and Daikoku T: Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus types 1 and 2. J Virol 65: 4520-4524, 1991.
24. Yura Y, Kusaka J, Bando T, Yamamoto S, Yoshida H and Sato M: Enhancement of herpes simplex virus-induced polykaryocyte formation by 12-O-tetradecanoyl phorbol 13-acetate: Association with the reorganization of actin filaments and cell motility. Intervirology 43: 129-138, 2000.
25. Kasuya H, Mizuno M, Yoshida J, Nishiyama Y, Nomoto S and Nakao A: Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy. J Surg Oncol 74: 214-218, 2000.
26. Lou E, Kellman RM and Shillitoe EJ: Effect of herpes simplex virus type-1 on growth of oral cancer in an immunocompetent, orthotopic mouse model. Oral Oncol 38: 349-356, 2002.
27. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B and Whitley RJ: Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 57: 1502-1509, 1997.
28. Wheeler CE: The effect of temperature upon the production of herpes simplex virus in tissue culture. J Immunol 81: 98-106, 1958.
29. 134. 5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide. Cancer Gene Ther 13: 780-791, 2006.
30. Korzeniewski C and Callewaert DM: An enzyme-release assay for natural cytotoxity. J Immunol Methods 64: 313-320, 1983.
31. Javier RT, Sedarati F and Stevens JG: Two avirulent herpes simplex viruses generate lethal recombinants in vivo. Science 234: 746-748, 1986.
32. Yirrell DL, Rogers CE, Blyth WA and Hill TJ: Experimental in vivo generation of intertypic recombinant strains of HSV in the mouse. Arch Virol 125: 227-238, 1992.
33. Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast RC Jr and Zhang X: Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res 9: 2727-2733, 2003.
34. Myers R, Greiner S, Harvey M, Soeffker D, Frenzke M, Abraham K, Shaw A, Rozenblatt S, Federspiel MJ, Russell SJ and Peng KW: Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther 12: 593-599, 2005.
35. Hoffmann D and Wildner O: Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy. Mol Cancer Ther 5: 2013-2022, 2006.